AnGes MG's HGF gene therapy finally set for Phase III start
Shares in AnGes MG have risen in Tokyo after the Japanese bioventure firmed up the timing for the start of a long-planned pivotal clinical trial with its lead therapeutic candidate.
Shares in AnGes MG have risen in Tokyo after the Japanese bioventure firmed up the timing for the start of a long-planned pivotal clinical trial with its lead therapeutic candidate.